Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 1057-1064

  Takeuchi, Tsutomu ^a   Tanaka, Yoshiya ^b   Iwasaki, Manabu ^c   Ishikura, Hiroaki ^d   Saeki, Satoshi ^d   Kaneko, Yuichiro ^d  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c SEIKEI UNIVERSITY   (Japan)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CREATINE KINASE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PEFICITINIB; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; 4-((5-HYDROXY-2-ADAMANTYL)AMINO)-1H-PYRROLO(2,3-B)PYRIDINE-5-CARBOXAMIDE; ADAMANTANE; ANTIRHEUMATIC AGENT; JANUS KINASE; NICOTINAMIDE;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INCIDENCE; JAPAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; OUTPATIENT; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; TREATMENT DURATION; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADAMANTANE; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JANUS KINASES; JAPAN; MALE; MIDDLE AGED; NIACINAMIDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84973364239     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208279     Document Type: Article

References (31)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13(Suppl 9):S237-51.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
4. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
5. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11 (Suppl 1):S1.
6. Smolen JS, Aletaha D, Koeller M, et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74.
7. Mavers M, Ruderman EM, Perlman H. Intracellular signal pathways: potential for therapies. Curr Rheumatol Rep 2009;11:378-85.
8. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228:273-87.
9. Package insert of XELJANZ ® (tofacitinib). NY, USA: Pfizer, 2014. Reference ID: 3502430.
10. Tanaka Y, Maeshima K, Yamaoka K. In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012;71(Suppl 2):i70-4.
11. Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 2013;23:415-24.
12. Tanaka Y, Takeuchi T, Yamanaka H, et al. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015;25:514-21.
13. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
14. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
15. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
16. Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
17. van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
18. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95.
19. Yamazaki S, Inami M, Ito M, et al. ASP015K: a novel JAK inhibitor demonstrated potent efficacy in adjuvant-induced arthritis model in rats. Arthritis Rheum 2012;64 (Suppl 10):2084.
20. Papp K, Pariser D, Catlin M, et al. A phase 2a randomised, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase ( JAK) inhibitor, in patients with moderate to severe psoriasis. Br J Dermatol 2015;173:767-76.
21. Zhu T, Sawamoto T, Valluri U, et al. Pharmacokinetics, safety, and tolerability of ASP015K, a novel Janus kinase inhibitor, in healthy volunteers. Ann Rheum Dis 2013;72(Suppl 3):898.
22. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
24. Fransen J, van Riel PL. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(Suppl 39):S93-9.
25. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
26. Posthumus MD, Limburg PC, Westra J, et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) 1999;38:1081-7.
27. Kubo S, Yamaoka K, Kondo M, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis 2014;73:2192-8.
28. Wang SP, Iwata S, Nakayamada S, et al. Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Ann Rheum Dis 2014;73:2213-15.
29. Disclosed document for new drug application of XELJANZ ® (tofacitinib). Pfizer, 2015.
30. Vyas D, O'Dell KM, Bandy JL, et al. Tofacitinib: The first Janus kinase ( JAK) inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2013;47:1524-31.
31. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004;5:253.